Latest news with #Becton
Malaysian Reserve
6 days ago
- Business
- Malaysian Reserve
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD). Known as 'XTRACT,' this prospective, multi-center, single-arm, post-market registry study will assess the clinical performance of the Rotarex™ Atherectomy System in the treatment of U.S. patients with PAD lesions. The XTRACT Registry is being led in partnership with Co-Principal Investigators, Dr. Prakash Krishnan, an interventional cardiologist, and Dr. Todd Berland, a vascular surgeon. The registry will enroll up to 600 patients at approximately 100 clinical sites across the United States, with the first patient enrollment expected later this year. Clinical follow-up evaluations will occur after 30 days, 6 months and 12 months post-procedure to assess safety and effectiveness of outcomes. 'This registry will provide valuable data to support clinical decision-making and enhance patient outcomes in the management of PAD,' said Dr. Krishnan. 'The Rotarex™ System has been extensively studied internationally, and we are excited to further evaluate its adaptability in treating a wide range of PAD lesions within the U.S. patient population.' The Rotarex™ Atherectomy System is a minimally invasive solution designed to efficiently remove both plaque and thrombus in peripheral arteries. Offering dual indications as both an atherectomy and thrombectomy device, the Rotarex™ Atherectomy System is a proven tool for treating PAD. 'The XTRACT Registry is the first comprehensive registry aimed at providing key insights into the real-world applications of the Rotarex™ System,' said Rima Alameddine, worldwide president of BD Interventional-Peripheral Intervention. 'This study underscores our unwavering commitment to optimizing treatment strategies in partnership with leading physicians to improve patient care.' PAD is a potentially debilitating disease that is estimated to affect more than 21 million Americans and more than 200 million people worldwide and can lead to increased risk of cardiovascular complications and lower limb amputation.1,2 The XTRACT Registry underscores BD's ongoing commitment to innovative technological development and evidence-based research that support physicians and improve patient outcomes. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Troy Kirkpatrick Adam Reiffe BD Public Relations BD Investor Relations 858.617.2361 201.847.6927 1 Yost, Mary. The Current U.S. Prevalence of Peripheral Arterial Disease. Vascular Disease Management. 2023;20(4):E67-E732 Allison MA, Armstrong DG, Goodney PP, et al. Health Disparities in Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2023;148:286-296. doi:10.1161/CIR.0000000000001153
Yahoo
6 days ago
- Business
- Yahoo
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD). Known as "XTRACT," this prospective, multi-center, single-arm, post-market registry study will assess the clinical performance of the Rotarex™ Atherectomy System in the treatment of U.S. patients with PAD lesions. The XTRACT Registry is being led in partnership with Co-Principal Investigators, Dr. Prakash Krishnan, an interventional cardiologist, and Dr. Todd Berland, a vascular surgeon. The registry will enroll up to 600 patients at approximately 100 clinical sites across the United States, with the first patient enrollment expected later this year. Clinical follow-up evaluations will occur after 30 days, 6 months and 12 months post-procedure to assess safety and effectiveness of outcomes. "This registry will provide valuable data to support clinical decision-making and enhance patient outcomes in the management of PAD," said Dr. Krishnan. "The Rotarex™ System has been extensively studied internationally, and we are excited to further evaluate its adaptability in treating a wide range of PAD lesions within the U.S. patient population." The Rotarex™ Atherectomy System is a minimally invasive solution designed to efficiently remove both plaque and thrombus in peripheral arteries. Offering dual indications as both an atherectomy and thrombectomy device, the Rotarex™ Atherectomy System is a proven tool for treating PAD. "The XTRACT Registry is the first comprehensive registry aimed at providing key insights into the real-world applications of the Rotarex™ System," said Rima Alameddine, worldwide president of BD Interventional-Peripheral Intervention. "This study underscores our unwavering commitment to optimizing treatment strategies in partnership with leading physicians to improve patient care." PAD is a potentially debilitating disease that is estimated to affect more than 21 million Americans and more than 200 million people worldwide and can lead to increased risk of cardiovascular complications and lower limb amputation.1,2 The XTRACT Registry underscores BD's ongoing commitment to innovative technological development and evidence-based research that support physicians and improve patient outcomes. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Troy Kirkpatrick Adam Reiffe BD Public Relations BD Investor Relations 858.617.2361 201.847.6927 1 Yost, Mary. The Current U.S. Prevalence of Peripheral Arterial Disease. Vascular Disease Management. 2023;20(4):E67-E732 Allison MA, Armstrong DG, Goodney PP, et al. Health Disparities in Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2023;148:286-296. doi:10.1161/CIR.0000000000001153 View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference
FRANKLIN LAKES, N.J., May 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 2:00 pm Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, A replay of the event will be available on the same webpage following its conclusion. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts:Media: Investors: Troy Kirkpatrick Adam Reiffe VP, Public RelationsSr. Director, Investor Relations 858.617.2361201.847.6927 View original content: SOURCE BD (Becton, Dickinson and Company) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fashion Value Chain
7 days ago
- Health
- Fashion Value Chain
BD Safe Emergency Seminar Launched to Provide Rich Knowledge Sharing Platform for Emergency Department Doctors
To raise awareness and foster discussions on the safety of healthcare workers (HCWs) in emergency departments, BD (Becton, Dickinson and Company) has recently launched the 'Safe Emergency Seminar' series across locations in India. BD safe emergancy seminar being conducted across India The emergency departments in hospitals typically demand high efficiency, which, in turn, increases the risk of blood exposure, blood splashes, and needlestick injuries (NSIs). Such incidents can expose healthcare workers to serious diseases like Hepatitis A, Hepatitis B, and HIV. The BD Safe Emergency seminar aims to provide a platform to bring together doctors from Emergency departments from across hospitals in each city to convene upon and discuss best practices for healthcare worker safety in high- efficiency demanding environment. Commenting on the Safe Emergency seminar series, Atul Grover, Managing Director, BD India/South Asia said, 'Our Safe Emergency seminar is a concerted effort to bring the spotlight on healthcare worker safety especially in dynamic and high efficiency demanding environments. We are committed to providing a platform for creating awareness and sharing best practices on this pertinent topic. This initiative is part of BDs broader commitment to ensuring the well-being of healthcare professionals and enhancing patient outcomes in alignment with our purpose of advancing the world of health.' The Safe Emergency seminars organized across cities featured in-depth scientific discussions on the burden of blood exposure, sharp safety, and vascular access in emergency departments. Experts from leading city hospitals shared valuable insights and data on needle stick injuries (NSI), blood exposure and splash thereby reinforcing the need for stringent safety protocols to protect healthcare workers. The discussions were followed by case studies that illustrated real-world scenarios and the effectiveness of various safety measures. About BD-India BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care. Disclaimer The image used in this press release is a stock photo and is for illustrative purpose only. The person(s) depicted herein are models. All content herein is protected by copyright, trademark and other intellectual property rights, as applicable, owned by or licensed to Becton Dickinson or its affiliates unless otherwise indicated.
Yahoo
7 days ago
- Business
- Yahoo
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck
The Saudi Arabia research antibodies market, valued at USD 10.52 Million in 2024, is projected to reach USD 12.71 Million by 2030, growing at a CAGR of 3.40%. This growth is fueled by expanding life sciences and R&D investments. Key challenges include high costs and reliance on imports. Custom antibody services and advances in personalized medicine are emerging trends. Major players like Cell Signaling Technology and Becton, Dickinson and Company dominate the market. The report covers technology and application insights and offers customization options for company-specific data. Saudi Arabian Research Antibodies Market Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Research Antibodies Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Saudi Arabia Research Antibodies Market, valued at USD 10.52 Million in 2024, is projected to grow to USD 12.71 Million by 2030, reflecting a CAGR of 3.40%. This growth trajectory is fueled by the expansion of the life sciences sector, increased R&D investments, and a heightened focus on biomedical research across the Kingdom. Research antibodies, essential tools in molecular biology, immunology, and biochemistry, are becoming vitally important for detecting, analyzing, and quantifying proteins and biological molecules. As Saudi Arabia aims to become a leader in biotechnology under its Vision 2030 initiative, the demand for high-quality research antibodies is set to rise. Local and international suppliers are increasingly catering to the needs of the country's burgeoning research community. Nevertheless, challenges such as the limited availability of domestically produced antibodies persist, leading to a dependency on imports. Key Market Drivers The growth of Saudi Arabia's healthcare industry significantly drives the research antibodies market. As healthcare infrastructure expands, driven by Vision 2030, the demand for advanced research tools like antibodies has increased. These antibodies are crucial for medical research and diagnostics, allowing for in-depth disease studies, treatment development, and improved diagnostic accuracy. A significant factor propelling market growth is the focus on disease prevention and personalized medicine. In January 2025, King Faisal Specialist Hospital & Research Center announced updates to its Biobank Center, marking a pivotal advancement in healthcare and medical research aligned with the objectives of Saudi Vision 2030. Key Market Challenges Expensive antibody costs pose challenges in the market, especially for specialized applications. The complexity involved in developing, producing, and controlling the quality of these antibodies results in high costs, impacting research budgets of academic institutions and biotech companies. Additionally, reliance on imported antibodies increases costs due to shipping, import taxes, and currency fluctuations, making cutting-edge research tools less accessible. Key Market Trends Custom antibody services have emerged as a significant trend, catering to the need for highly specific antibodies tailored for various research projects and diagnostic applications. This trend is driven by Saudi Arabia's increasingly complex research landscape, particularly in fields like personalized medicine, drug development, and precision diagnostics. Companies like GenScript offer comprehensive custom polyclonal antibody production services, ensuring quality and quick turnaround times, which are crucial for advancing medical research and diagnostics. Report Scope Key Market Players Cell Signaling Technology, Inc. Salima Trading Corp. AJ Jeel Medical & Trading Co. Ltd. Becton, Dickinson and Company Merck Limited Saudi Arabia Research Antibodies Market, By Technology: Immunohistochemistry Immunofluorescence Western blotting Flow cytometry Immunoprecipitation ELISA Others Saudi Arabia Research Antibodies Market, By Application: Infectious Diseases Immunology Oncology Stem Cells Neurobiology Others Saudi Arabia Research Antibodies Market, By Region: Eastern Western Northern & Central Southern Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $10.52 Million Forecasted Market Value (USD) by 2030 $12.71 Million Compound Annual Growth Rate 3.4% Regions Covered Saudi Arabia For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Research Antibodies Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
